Quince Therapeutics stockholders approved a Certificate of Amendment increasing authorized common shares from 250,000,000 to 275,000,000, effective October 6, 2026. The vote also ratified the adoption of the 2026 Equity Incentive Plan with an initial reserve of approximately 2.2 million shares and the 2026 Employee Stock Purchase Plan with a 142,045-share reserve. Additionally, shareholders approved issuances related to Series C Preferred conversion and Orphai warrants under Nasdaq rules. Quince Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for rare diseases.
